Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts

Industry Overview - The biopharmaceutical industry is known for producing dramatic market movements due to clinical trial results or regulatory decisions [1] Company Focus: Iovance Biotherapeutics - Iovance Biotherapeutics is pioneering a new approach to treating cancer, with its first therapy, Amtagvi, showing strong sales despite the stock being down 88% from its 2021 peak [2] - The stock is currently underappreciated, with analysts predicting a potential 280% gain from recent prices, targeting $23.77 per share [3] Product Success: Amtagvi - Amtagvi, approved by the FDA for advanced-stage melanoma, has shown promising results, shrinking tumors in 31.5% of patients in clinical trials [5][7] - The therapy involves a complex process of harvesting tumor-infiltrating lymphocytes (TILs) from each patient and requires a weeklong lymphodepletion process before infusion [6] - Third-quarter sales of Amtagvi reached $42 million, with Proleukin sales adding $16.5 million [7] Future Prospects - Iovance expects total 2025 revenue to be between $450 million and $475 million, with potential European approval of Amtagvi expected in the second half of the year [8] - The company is expanding its reach with the phase 3 Tilvance-301 trial for frontline melanoma and a phase 2 lung cancer study, with updated data expected later this year [9] - Iovance is also developing a next-generation TIL therapy, IOV-4001, which aims to improve the effectiveness of TILs by targeting programmed cell death protein 1 [10] Financial Performance - Despite strong product sales, Iovance's gross margin is narrow due to the high manufacturing costs of Amtagvi, with gross profit at 32% of top-line revenue in the third quarter [11] - The company reported $397 million in cash at the end of September 2024, after burning through $294 million in the first nine months of the year [12]